Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is December - November.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov 30, 2025	Nov 30, 2024	Nov 30, 2023	Nov 30, 2022	Nov 30, 2021
Net Income	-264.46	-193.57	-143.95	-180.36	-117.19
Depreciation & Amortization	18.26	15.13	12.25	9.61	5.28
Other Amortization	0.6	1.3	1.4	1.2	0.8
Loss (Gain) From Sale of Assets	0.09	0.03	0.56	0.01	0.13
Loss (Gain) From Sale of Investments	-10.32	-11.29	-5.42	0.43	1.71
Stock-Based Compensation	37.97	33.93	33.67	28.13	15.8
Other Operating Activities	-	0.29	-	0.2	-
Change in Accounts Receivable	-	-	-	6	-6
Change in Accounts Payable	-0.63	5.21	1.61	0.09	1.59
Change in Unearned Revenue	-36.98	-28.55	19.51	-26.63	14.25
Change in Income Taxes	-	-	-	-	3.64
Change in Other Net Operating Assets	6.01	4.94	-1.01	1.52	-4.37
Operating Cash Flow	-249.47	-172.58	-81.37	-159.81	-84.37
Capital Expenditures	-14	-9.27	-8.4	-12.24	-5.66
Investment in Securities	161.86	-248.44	76.7	39.44	-102.59
Investing Cash Flow	147.85	-257.71	68.3	27.2	-108.25
Issuance of Common Stock	238.64	485.68	3.22	22.43	164.13
Repurchase of Common Stock	-	-0.02	-	-	-
Other Financing Activities	-	-	-	94.76	-10.24
Financing Cash Flow	238.64	485.67	3.22	117.19	153.88
Net Cash Flow	137.03	55.37	-9.85	-15.42	-38.73
Free Cash Flow	-263.47	-181.86	-89.77	-172.05	-90.03
Free Cash Flow Margin	-313.73%	-333.38%	-116.60%	-445.42%	-302.61%
Free Cash Flow Per Share	-3.04	-2.71	-1.65	-3.54	-2.10
Cash Income Tax Paid	-	-	-	-	0.48
Levered Free Cash Flow	-143.99	-85.9	-41.93	-79.42	-37.7
Unlevered Free Cash Flow	-143.99	-85.9	-41.93	-79.42	-37.7
Change in Working Capital	-31.6	-18.4	20.12	-19.02	9.11

Updated Nov 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q